165results about "Antigen carriers" patented technology

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.

Disclosed herein are compositions and methods for eliciting an immune response against both influenza virus and coronavirus. Provided herein are compositions and methods of use thereof, the compositions comprising (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, where the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, where each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and / or ameliorate autoimmune diseases.

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The present invention generally relates to an immunogenic construct,useful for redirecting an EBV-existing immune response towards an undesired target cell and / or microorganism,to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present invention pertains to specific bioparticules at the surface of which are expressed multimeric protein. The bioparticles according to the present invention comprise an envelope consisting of a plasma membrane; and at least one type I or II transmembrane fusion protein anchored in said membrane, said fusion protein comprising successively a) a first monomer of a multimeric protein of interest, b) a coiled-coil domain or oligomerization sequence; and c) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. Fragments a) and b) are exposed at the surface of the bioparticle, and fragment a) is bound to a second monomer of said multimeric protein by means of a bond which is not a peptide bond. The bioparticles according to the present invention can be used in therapy such as immunotherapy. The present invention also pertains to methods for producing such bioparticles.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

To provide methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature.SOLUTION: The method comprises mixing an antigen and virus particles in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV2).SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicine and disease prevention and treatment, and particularly relates to an SSEA4 conjugated virus-like particle anti-cancer vaccine as well as a preparation method and application thereof. Specifically, according to the vaccine, an SSEA4 antigen is efficiently synthesized through a chemical enzyme method, then the SSEA4 antigen is covalently coupled with a virus-like particle (VLP), the SSEA4 antigen and the VLP are combined with a monophosphoryl lipid A adjuvant with high safety, an organism can be induced to generate strong and lasting SSEA4-resistant humoral immune response, the generated antibody can specifically recognize and kill SSEA4 positive tumor cells, and the SSEA4 positive tumor cells can be effectively killed. Meanwhile, good safety is shown in an animal model, a new solution is provided for immunotherapy of SSEA4 positive tumors, and therefore the SSEA4 positive tumor immunotherapy polypeptide has wide application prospects and market value.

The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.

The present disclosure generally relates to spherical nucleic acids (SNAs), which are nanostructures having a core surrounded by radial presentation of oligonucleotides that can target multiple classes of immune cells. Methods of making and using nanoparticles are also provided herein. In some aspects, the present disclosure provides spherical nucleic acids (SNAs), comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides bound to the outer surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen and a second antigen that is a major histocompatibility complex type II (MHC-II) antigen.

The present invention relates to a vaccine composition including double-stranded DNA delivered into cells via gold nanoparticles, and more particularly, to a vaccine composition characterized in that the double-stranded DNA is derived from a viral, bacterial or cancer gene and expresses an antigen to induce an immune response.

The invention belongs to the technical field of biological medicines, and particularly relates to a universal vaccine constructed by taking lipopolysaccharide or analogues thereof as universal antigens and adjuvants, the vaccine can establish inherent immune memory and adaptive immune memory at the same time after being inoculated, instant quick prevention and control can be realized aiming at sudden epidemic situations, and the immunologic function of the vaccine is improved. And a plurality of diseases can be prevented or treated. Besides, the lipopolysaccharide analogue and an amphiphilic substance are assembled into nanoparticles by utilizing the hydrophobicity of a lipid A structure of the lipopolysaccharide analogue and the hydrophilicity of a glycosyl group, and through ligand modification, the targeting property of the vaccine to antigen presenting cells is improved, and the safety of the lipopolysaccharide or the analogue thereof in application to universal vaccines, adjuvants and medicines is improved.

The invention discloses a silicon dioxide carrier-based HIV (Human Immunodeficiency Virus) MPER polypeptide nano vaccine as well as a preparation method and application thereof. According to the preparation method, special silicon dioxide nanoparticles are used as a carrier, and MPER polypeptide is connected to the surface of the carrier based on the atomic crystal characteristics (including large specific surface area and certain thermal stability) of the carrier, so that oligomerization of the polypeptide is reduced, and the effective antigen immunity is improved. In order to further realize the enrichment of the antigen, the MPER polypeptide is treated by adopting a four-limb peptide mode, so that a more stable system can be formed after the MPER polypeptide is coupled with the nanoparticles. Based on a stable polypeptide structure and chemical properties thereof, the polypeptide has better rigidity, the variability is reduced, the antigen quality is ensured, and the antigen activity is improved. The finally obtained nano antigen can effectively enter the body to induce a high-titer neutralizing antibody, and has great significance for controlling HIV-1 transmission.

The present invention generally relates to methods and composition matters for delivery of a cargo to a living cell over producing immunoproteasomes. More specifically the invention disclosed is a molecular construct that delivers a cargo, for diagnostic or therapeutic purposes, to a living cell. Methods of use and composition matters are within the scope of this disclosure.

The present invention relates to a non-injectable drug delivery system using mucoadhesive nanoparticles, and to mucoadhesive nanoparticles and a method for producing the same, which prevent deformation of the nanoparticles due to mucosal moisture, etc., and strengthen mucoadhesiveness to prevent loss by binding a mucoadhesive polymer to the surface of the nanoparticles. The present invention also relates to a composition for maturing antigen-presenting cells, a composition for treating infectious diseases, and a composition for treating cancer, which comprise the mucoadhesive nanoparticles. The present invention also relates to mucoadhesive nanoparticles loaded with immune active substances (such as antigens and adjuvants) for cancer treatment and immunotherapy based on antigen-presenting cells including dendritic cells (DCs), and a composition for immune anti-cancer treatment comprising the same.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.

The present disclosure generally relates to methods of identifying and / or selecting self-replicating RNA (srRNA) delivery systems suitable for biomedical applications. More particularly, the disclosure relates to methods of identifying and / or selecting srRNA delivery systems using a combination of critical quality attributes for srRNA vaccines and biotherapeutics. Also provided are srRNA compositions, formulations obtained by the methods of the disclosure, as well as methods for inducing a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions.

Provided in the present invention are a hepatitis B virus receptor OATP and the use thereof. Specifically, provided in the present invention is the use of a substance in the preparation of an agent for preventing and / or treating hepatitis B virus (HBV) and / or hepatitis D virus (HDV) infections in an animal or diseases related to said infections, wherein the substance prevents or reduces the interaction between HBV and / or HDV and an organic anion transporting polypeptide (OATP) in the animal, and / or prevents or reduces the expression and / or function of OATP in the animal. Further provided in the present invention are a cell model and an animal model having susceptibility to HBV and / or HDV that are obtained by means of transferring an exogenous SLCO gene into a cell or expressing an exogenous OATP protein, and a method for establishing the models; a method for delivering a drug by means of targeting OATP, and a drug delivery vehicle targeting OATP; and an OATP-targeted delivery polypeptide vehicle derived from a hepadnaviridae surface antigen.

An immunomodulatory delivery system includes a hydrogel, a first immunomodulatory cargo encapsulated in the cargo, and a second immunomodulatory cargo encapsulated in the hydrogel. The hydrogel includes a polymer non-covalently crossed-linked with a plurality of nanoparticles. The first immunomodulatory cargo is smaller than the second immunomodulatory cargo. A ratio of a diffusivity of the first immunomodulatory cargo through the hydrogel to a diffusivity of the second immunomodulatory cargo through the hydrogel is less than 3.

Disclosed herein is a bioactive polymer for forming a solution and / or hydrogel to stabilise one or more pharmaceutically active agents prior to, during or post-administration, the polymer comprising a first monomer for binding water, a second monomer for imparting mechanical properties to the scaffold; optionally, a third monomer for binding to a natural or synthetic peptide or protein (NSPP); and a fourth monomer for imparting phase-transition behaviour. Preferably, the first monomer is OEGMA; the second monomer is PLA / HEMA; the third monomer is NAS; and the fourth monomer is NIPAAm, and the polymer comprises: OEGMA in an amount of from about 1 to about 15 mol%; PLA / HEMA in an amount of from 5 to about 50 mol%; NAS in an amount of from 0 to about 15 mol%; and NIPAAm in an amount of up to about 85 mol%.

The present disclosure relates to immunostimulatory compositions that are effective in eliciting immune responses in avian species. More specifically, these immunostimulatory compositions comprise an immunomodulator composition and an immunostimulatory oligonucleotide that when administered stimulate toll-like receptor 21.

A method of encapsulating a biomolecule in a silica shell to form a particle, the method comprising: • a) hydrolyzing a mixture of silica precursors, said mixture comprising a functionalized silica precursor comprising a Si-C bond and a non-functionalized silica alkoxide precursor, • b) directly contacting the hydrolyzed precursors with an aqueous solution comprising the biomolecule and • c) encapsulating the biomolecule in a silica shell to form a particle, such that at least a portion of the silica on the interior surface of the silica shell is functionalized and comprises a Si-C bond.

The present disclosure relates to methods of treating cancer in subjects by a two-part treatment regime comprising a first treatment that provides antigen-specific CD4+ and / or CD8+ T cells in the subject and a second treatment, administered after a time interval, that induces systemic and / or tumor-specific inflammation in the subject.

A nucleic acid coding for a modified Spike protein from a virus of the Orthocoronavirinae subfamily, an extracellular vesicle expressing a modified Spike protein from a virus of the Orthocoronavirinae subfamily, and a population of the extracellular vesicles. Also, the use of the nucleic acid, extracellular vesicle or population of extracellular vesicles for use in a method of immunizing a subject against a virus of the Orthocoronavirinae subfamily, in methods of production and screening of neutralizing antibodies.

The invention relates to an autologous cancer vaccine, and to a method of producing same, comprising the following steps: a) extracting proteins from a serum or plasma sample obtained from a cancer patient; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and / or tricalcium phosphate.